E-LIB Suche - Ergebnisse für: Chetanraj Bhamare

1

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): ..:

Kulkarni, Prasad S. ; Padmapriyadarsini, Chandrasekaran ; Vekemans, Johan...
Human Vaccines & Immunotherapeutics. 20 (2024) 1 - p. , 2024

Link: https://doi.org/10.1080/..

2

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vacc..:

Kulkarni, Prasad S. ; Kadam, Abhijit ; Godbole, Sheela...
The Lancet Regional Health - Southeast Asia. 10 (2023) - p. 100139 , 2023

Link: https://doi.org/10.1016/..

3

Active safety surveillance of rabies monoclonal antibody an..:

Kang, Gagandeep ; Lakhkar, Anand ; Bhamare, Chetanraj...
The Lancet Regional Health - Southeast Asia. 14 (2023) - p. 100207 , 2023

Link: https://doi.org/10.1016/..

4

A Phase 3, randomized, non-inferiority study of a heterolog..:

Kulkarni, Prasad S. ; Gunale, Bhagwat ; Kohli, Sunil...
Scientific Reports. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

5

Post-marketing safety surveillance of the rotavirus vaccine..:

Kang, Gagandeep ; Lakhkar, Anand ; Bhamare, Chetanraj...
Vaccine: X. 15 (2023) - p. 100362 , 2023

Link: https://doi.org/10.1016/..

6

A phase 2/3, participant-blind, observer-blind, randomised,..:

Kulkarni, Prasad S ; Padmapriyadarsini, Chandrasekaran ; Vekemans, Johan...
eClinicalMedicine. 42 (2021) - p. 101218 , 2021

Link: https://doi.org/10.1016/..

7

Safety and tolerability of a liquid bovine rotavirus pentav..:

Anil, K. ; Desai, Sajjad ; Bhamare, Chetanraj...
Vaccine. 36 (2018) 12 - p. 1542-1544 , 2018

Link: https://doi.org/10.1016/..

8

A Phase 3, randomized, non-inferiority study of a heterolog..:

Prasad S. Kulkarni ; Bhagwat Gunale ; Sunil Kohli...
https://doi.org/10.1038/s41598-023-43578-w. , 2023

Link: https://doi.org/10.1038/..

9

Post-marketing safety surveillance of the rotavirus vaccine..:

Gagandeep Kang ; Anand Lakhkar ; Chetanraj Bhamare...
http://www.sciencedirect.com/science/article/pii/S2590136223001031. , 2023

Link: https://doi.org/10.1016/..

10

Active safety surveillance of rabies monoclonal antibody an..:

Gagandeep Kang ; Anand Lakhkar ; Chetanraj Bhamare...
http://www.sciencedirect.com/science/article/pii/S2772368223000677. , 2023

Link: https://doi.org/10.1016/..

11

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vacc..:

Prasad S. Kulkarni ; Abhijit Kadam ; Sheela Godbole...
http://www.sciencedirect.com/science/article/pii/S2772368222001561. , 2023

Link: https://doi.org/10.1016/..

12

Post-marketing safety surveillance of the rotavirus vaccine..:

Kang, Gagandeep ; Lakhkar, Anand ; Bhamare, Chetanraj...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430202/. , 2023

Link: http://www.ncbi.nlm.nih...

13

A Phase 3, randomized, non-inferiority study of a heterolog..:

Kulkarni, Prasad S ; Gunale, Bhagwat ; Kohli, Sunil...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547846/. , 2023

Link: http://www.ncbi.nlm.nih...

14

Active safety surveillance of rabies monoclonal antibody an..:

Kang, Gagandeep ; Lakhkar, Anand ; Bhamare, Chetanraj...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363514/. , 2023

Link: http://www.ncbi.nlm.nih...

15

Prescribing practices of topical corticosteroids in the out..:

Suvarna S Rathod ; Vijay M Motghare ; Vinod S Deshmukh...
http://www.e-ijd.org/article.asp?issn=0019-5154;year=2013;volume=58;issue=5;spage=342;epage=345;aulast=Rathod. , 2013

Link: https://doi.org/10.4103/..